Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:17:02.661Z.
Calculation as of: 2026-10-06T16:17:02.661Z.
Quote observation: 2026-10-06T16:15:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 87a3ef4e55b06d985fb23947e4d9ae6563d80488a3a61227015f8099389db825
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $559702.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $669300.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $809925.00 | N/A | 0.43 | 0.43 | 0.34 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $816286.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $845829.00 | N/A | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $858810.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $859931.00 | N/A | 0.00 | 0.00 | 0.00 |
| GlucoTrack, Inc. (GCTK)vs › | $869976.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $94810.00 | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.61
Forward EPS (Est.)
$-2.88
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
